Zofia Piotrowska, MD

This closing segment addresses how first-line choice shapes later options and how to approach progression.

This segment presents a contrasting case: an older patient with a classic sensitizing mutation, lower disease burden, no central nervous system involvement, reduced renal function, a prior thromboembolic event, and meaningful access and support constraints.

This segment applies the preceding data to a higher-risk patient: a fit, newly diagnosed individual with a classic sensitizing mutation, a co-occurring high-risk alteration, high disease burden, and small asymptomatic brain metastases.

This segment turns from data to the patient conversation, focusing on the preconceptions people bring to treatment decisions.

This segment addresses the chemotherapy-free combination of amivantamab and lazertinib as a first-line option and its distinct safety profile.

This segment focuses on combining osimertinib with platinum-pemetrexed chemotherapy as a first-line intensification strategy.

This segment examines single-agent osimertinib as the foundation of first-line EGFR-mutated NSCLC therapy and the benchmark against which combination strategies are measured.

With the molecular picture established, the discussion turns to how a confirmed EGFR mutation translates into a first-line treatment decision.

This opening segment frames how first-line management of EGFR-mutated advanced non-small cell lung cancer has shifted from a single-agent standard to several guideline-preferred regimens, each carrying distinct efficacy, safety, and administration considerations.

In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.

Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer.